Gosling J P
Department of Biochemistry, University College Galway, IR.
Scand J Clin Lab Invest Suppl. 1991;205:95-104. doi: 10.3109/00365519109104607.
The pace of the development and commercialization of immunoassay methodology has been so great, that the parallel development of ways to ensure comparability between the results of different immunoassays for the same substance has fallen behind. If, as is the case with many hapten analytes, the analyte is chemically defined, homogeneous and available at very high purity, the rigorous standardization of different immunoassays developed to determine the same would appear to be feasible. However, many published details of external quality assessment schemes and of studies on the comparability of commercial assays indicate that the results of immunoassays for hapten analytes are not generally and reliably comparable. Lack of comparability is most marked for assays detecting a variety of analyte subforms or metabolites. This problem is surveyed with respect to the variability of hapten immunoassays, factors related to details of immunoassays. Finally, the assessment of assay comparability and some potential strategies for improving it are discussed.
免疫分析方法的开发和商业化步伐如此之快,以至于确保针对同一物质的不同免疫分析结果具有可比性的方法的同步开发已经落后。如果像许多半抗原分析物那样,分析物在化学上是明确的、均质的且具有非常高的纯度,那么为测定同一分析物而开发的不同免疫分析的严格标准化似乎是可行的。然而,许多已发表的外部质量评估计划的细节以及关于商业检测可比性的研究表明,半抗原分析物的免疫分析结果通常并不可靠地具有可比性。对于检测多种分析物亚形式或代谢物的检测方法,缺乏可比性最为明显。针对半抗原免疫分析的变异性、与免疫分析细节相关的因素,对这一问题进行了综述。最后,讨论了检测可比性的评估以及一些改善可比性的潜在策略。